Clinical Trial Update: BXCL501 for Agitation in Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study of BXCL501 for agitation in schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• BXCL501 (dexmedetomidine)

Snippet

Sponsor: Yale University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED